Supplemental Data Methods

Sample processing
Five mL of venous blood was collected from each donor and placed in a separating gel vacuum tube. To harvest the cell-free serum, each blood sample was immediately centrifuged at 3,000 rpm for 10 min, followed by a second centrifugation at 12,000 rpm for 5 min. The serum supernatant was recovered and stored at -80 o C until further analysis.
TDLA technology
TDLA technology was performed as follow descriptions. Briefly, 3 μL total RNA were added to 4.5 μL of the RT reaction mix (Megaplex RT Primers 10X, dNTPs with dTTP 100mmol, MultiScribe Reverse Transcriptase 50U/μL, 10X RT Buffer, MgCl2 25 mmol, RNase
Inhibitor 20 U/μL and nuclease-free water). After incubation on ice for 5 min, reverse transcription was performed using a thermal cycler (UNO-ThermobloCk, Biometra, Göttingen, Germany). MicroRNA profiling of 739 different human miRNAs was then performed using the TaqMan Low Density Array (TaqMan Array Human MicroRNA A+B Cards Set v3.0). In order to generate enough miRNA cDNA templates for the following real-time RCR, a pre-amplification was performed after the reverse transcription. All steps were performed using a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) and all reactions were performed following the protocols of the manufacturer. The expression data for the miRNA were presented as threshold cycle (CT) values.
Quantification of miRNAs by probe-based RT-qPCR
A TaqMan probe-based RT-qPCR assay was performed according to the manufacturer's instructions (Applied Biosystems) with a minor modification. The resulting Ct values were determined using fixed threshold settings. Briefly, the reverse transcription reaction was carried out in 10 μL mixture containing 2 μL of extract RNA from serum, 1 μL of 10 mmol/L dNTPs, 0.5 μL of AMV reverse transcriptase (TaKaRa), 1 μL of a stem-loop RT primer (Applied Biosystems), 2 μL of 5 × reverse transcription buffer and 3. 
Risk score analysis
Risk score analysis was performed to evaluate the associations between the expression levels of the serum miRNAs and CRC. The risk score of each miRNA, denoted as s, was set to 1 if the expression level was greater than the upper 95% reference interval for the corresponding miRNA level in controls and to 0 otherwise.
A risk score function (RSF) to predict CRC was defined according to a linear combination of the expression level for each miRNA. For example, the RSF for sample i using information from six miRNAs was: rsfi=∑6j-1Wj.sij. In the above equation, sij is the risk score for miRNA j on sample i, and Wj is the weight of the risk score of miRNA j. To determine the Ws, six univariate logistic regression models were fitted using the disease status with each of the risk scores. The regression coefficient of each risk score was used as the weight to indicate the contribution of each miRNA to the RSF. Samples were ranked according to their RSF and then divided into a high-risk group, representing the predicted CRC cases, and a low-risk group, representing the predicted control individuals. We then used frequency tables and ROC curves to evaluate the diagnostic effects of the profiling and to find the appropriate cutoff point.
Supplemental Data Table S1
The miRNAs recruited in the present study and their reported relevance to CRC. 
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Supplemental Data Table S2
Differentially expressed miRNAs in pre-operative CRC serum samples compared to healthy control serum samples determined by TLDA. 2 Difference between pre-operative CRC and post-operative CRC.
